{"id":"NCT00448916","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures","officialTitle":"A 12-month Open-label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2007-03-19","resultsPosted":"2014-12-02","lastUpdate":"2021-01-25"},"enrollment":54,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsies, Partial"],"interventions":[{"type":"DRUG","name":"Pregabalin","otherNames":[]}],"arms":[{"label":"Pregabalin","type":"EXPERIMENTAL"}],"summary":"The study will evaluate the long-term safety and tolerability of pregabalin in pediatric patients, age 1 month through 16 years, with partial onset seizures.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AE).","timeFrame":"12 Months","effectByArm":[{"arm":"Pregabalin: 1-23 Months","deltaMin":14,"sd":null},{"arm":"Pregabalin: 2-6 Years","deltaMin":13,"sd":null},{"arm":"Pregabalin: 7-11 Years","deltaMin":11,"sd":null},{"arm":"Pregabalin: 12-16 Years","deltaMin":9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Month","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":18,"countries":["United States","Mexico","South Korea"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081075&StudyName=Open-Label%20Extension%20Study%20Of%20Safety%20And%20Tolerability%20Of%20Pregabalin%20In%20Pediatric%20Patients%20With%20Partial-Onset%20Seizures"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":16},"commonTop":["Pyrexia","Upper respiratory tract infection","Otitis media","Constipation","Convulsion"]}}